ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0198

High Dose Intravenous Methylprednisolone Induces Rapid Improvement of Visual Acuity in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases

Nuria Vegas-Revenga1, José Luis Martin-Varillas2, Vanesa Calvo-Río3, Iñigo Gonzalez-Mazon4, Lara Sánchez-Bilbao5, Emma Beltrán Catalán6, Alejandro Fonollosa7, Ana Blanco8, Ana Blanco9, Miguel Cordero Coma10, Norberto Ortego11, Ignacio Torre12, Felix Hernandez13, Santiago Muñóz-Fernández14, Maria del Mar Esteban-Ortega14, Manuel Diaz-Llopis15, Joaquin Cañal5, Juan Antonio Ventosa5, Rosalía Demetrio-Pablo16, Lucia Cristina Dominguez Casas17, Santos Castañeda18, Iván Ferraz-Amaro19, Miguel Ángel gonzalez-Gay20 and Ricardo Blanco3, 1Hospital Galdakao, Galdakao, Spain, 2Hospital Sierrallana, Torrelavega, Spain, 3Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4H. U. Marques de Valdecilla, Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Hospital del Mar, Barcelona, Spain, 7Hospital Universitario de Cruces, Barakaldo, Spain, 8Hospital Universitario de Donostia, San Sebastián, 9Hospital Universitario de Donostia, Donostia, Spain, 10Hospital de León, Leon, Spain, 11Medicine Department, Universidad de Granada, Granada, Spain, 12Hospital Universitario de Basurto, Bilbao, Spain, 13Hospital Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain, 14Hospital Universitario Infanta Sofia, Madrid, Spain, 15Hospital Universitario La Fe, Valencia, Spain, 16Hospital Universitario de Marqués de Valdecilla, Santander, Spain, 17Hospital Universtario San Agustin, Oviedo, Spain, 18Hospital Universitario de la Princesa, Madrid, Spain, 19Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 20Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Meeting: ACR Convergence 2021

Keywords: IMMUNE MEDIATED INFLAMMATORY DISEASES, intravenous methylprednisolone, Uveitis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Rapid and effective remission-inducing therapy is mandatory in uveitis to avoid irreversible structural and functional damage. In some severe cases biological agents might be required (1-6). High-dose intravenous methylprednisolone (IVMP) may achieve prompt control of inflammation in most immune mediated inflammatory diseases (IMID), including non-infectious uveitis (NIU). The objective is to evaluate the efficacy and safety of IVMP pulse therapy in NIU of different IMID.

Methods: Multicentre study of 71 patients with severe uveitis who received IVMP. The underlying diseases were: Vogt-Koyanagi-Harada disease (VKHD) (n=24), Behçet disease (BD) (19), Sarcoidosis (5) and idiopathic NIU (23). The main outcome variable was Best-Corrected Visual Acuity (BCVA) estimated using the Snellen chart. BCVA that was assessed at 0 (basal), 2-5, 7, 15 and 30 days after IVMP. The results are expressed as mean ±SD in normally distributed variables, or as median [IQR] when are not. Comparison of continuous variables was performed using the Wilcoxon test.

Results: We studied 46♀/ 25♂ patients. The main features are shown in TABLE. IVMP dose ranged from 250 to 1000 mg/day administered for 3-5 consecutive days, the dose was established according to the presence or not of other systemic manifestations apart from uveitis. All of them had active intraocular inflammation at the moment of the study. BCVA values improved considerably after 1 month (FIGURE). No major side effects were observed.

Conclusion: High-dose IVMP pulse therapy is useful and safe for a prompt control of BCVA regardless of the underlying IMID.

REFERENCES
1. Vegas-Revenga N, et al. Am J Ophthalmol. 2019; 200:85-94. doi: 10.1016/j.ajo.2018.12.019
2. Calvo-Río V, et al. Clin Exp Rheumatol. 2014;32(4 Suppl 84): S54-7. PMID: 25005576
3. Santos-Gómez M, et al. Clin Exp Rheumatol. 2016;34(6 Suppl 102): S34-S40. PMID:27054359
4. Atienza-Mateo B, et al. Rheumatology (Oxford) 2018;57(5):856-864. doi: 10.1093/rheumatology/kex480.
5. Atienza-Mateo B, et al. Arthritis Rheumatol. 2019; 71(12):2081-2089. doi: 10.1002/art.41026.
6. Martín-Varillas JL, et al. Ophthalmology. 2018;125(9):1444-1451. doi: 10.1016/j.ophtha.2018.02.020

Table. Main features of 71 patients with NIU. Data are of affected eyes.

Figure. Improvement of best corrected visual acuity (BCVA).


Disclosures: N. Vegas-Revenga, None; J. Martin-Varillas, None; V. Calvo-Río, None; I. Gonzalez-Mazon, None; L. Sánchez-Bilbao, None; E. Beltrán Catalán, None; A. Fonollosa, None; A. Blanco, None; A. Blanco, None; M. Cordero Coma, None; N. Ortego, None; I. Torre, None; F. Hernandez, None; S. Muñóz-Fernández, None; M. Esteban-Ortega, None; M. Diaz-Llopis, None; J. Cañal, None; J. Ventosa, None; R. Demetrio-Pablo, None; L. Dominguez Casas, None; S. Castañeda, None; I. Ferraz-Amaro, None; M. gonzalez-Gay, None; R. Blanco, Brystol Myers Squibb, 6.

To cite this abstract in AMA style:

Vegas-Revenga N, Martin-Varillas J, Calvo-Río V, Gonzalez-Mazon I, Sánchez-Bilbao L, Beltrán Catalán E, Fonollosa A, Blanco A, Blanco A, Cordero Coma M, Ortego N, Torre I, Hernandez F, Muñóz-Fernández S, Esteban-Ortega M, Diaz-Llopis M, Cañal J, Ventosa J, Demetrio-Pablo R, Dominguez Casas L, Castañeda S, Ferraz-Amaro I, gonzalez-Gay M, Blanco R. High Dose Intravenous Methylprednisolone Induces Rapid Improvement of Visual Acuity in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/high-dose-intravenous-methylprednisolone-induces-rapid-improvement-of-visual-acuity-in-non-infectious-uveitis-of-different-immune-mediated-inflammatory-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-dose-intravenous-methylprednisolone-induces-rapid-improvement-of-visual-acuity-in-non-infectious-uveitis-of-different-immune-mediated-inflammatory-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology